Gelteq (GELS), a biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, priced its initial public offering of 1.3M ordinary shares at a price of $4.00 per share. The shares are listed on the Nasdaq under the symbol “GELS.” Benchmark is acting as the lead managing underwriter for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.